A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function

European Journal of Neurology

Volumn 5, Issue 2, 1998, Pages 181-186

  Dodd, S L ^a   Rowell, B A ^a   Vrabas, I S ^a   Arrowsmith, R J ^b   Weatherill, P J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Speywood Pharmaceuticals   (United Kingdom)

Author keywords

Fatigue; Muscle contractile properties; Neurotoxin

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUSCLE FATIGUE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE TONE; MUSCLE TWITCH; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIBIALIS ANTERIOR MUSCLE;

EID: 0031913160     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.1998.520181.x     Document Type: Article

References (18)

1. Buchman AS, Comella CL, Stebbins GT and Weinstein SL (1994). Determining dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia. Clinical Neuropharmacology 17:188-195.
2. Cichon JY, McCaffrey TY, Litchy WJ and Knops JL (1995). The effect of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 105:144-148.
3. Dolly JO, Black J, Williams RS and Melling J (1984). Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307:457-460.
4. Duchen LW (1970). Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. Journal of Neurology, Neurosurgery and Psychiatry 33:40-54.
5. Edgerton VR (1976). Neuromuscular adaptation to power and endurance work. Canadian Journal of Sports Sciences 1:49-58.
6. Fitts RH, McDonald KS and Schluter JM (1991). The determinants of skeletal muscle force and power: their adaptability with changes in activity pattern. Journal of Biomechanics 24:11-122.
7. Hambleton P and Pickett AM (1994). Dose standardisation of botulinum toxin. Lancet 344:474-475.
8. Hassan SM, Jennekens FGI and Veldman H (1995). Botulinum toxin-induced myopathy in the rat. Brain 118:533-545.
9. Holt D, Fredericks S, Algate D, Williams C, Arrowsmith RJ and Taylor JF (1995). Therapeutic botulinum toxin: localisation of proprietary formulations. Movement Disorders 10:385.
10. Jankovic J and Swartz K (1990). Botulinum toxin injections for cervical dystonia. Neurology 40:277-280.
11. Kraft SP and Lang AE (1988). Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Canadian Journal of Neurological Science 15:276-280.
12. Lange DJ, Brin MF and Warner CL (1987). Distant effects of local injection of botulinum toxin. Muscle Nerve 10:552-555.
13. Leiber R (1992). Skeletal Muscle Structure and Function: Implications for Rehabilitation and Sports Medicine. Baltimore, Williams and Wilkins.
14. Marion M-H, Sheehy M, Sangla S and Soulayrol S (1995). Dose standardisation of botulinum toxin. Journal of Neurology Neurosurgery and Psychiatry 59:102-103.
15. Maurri S and Barontini F (1990). Responsiveness of idiopathic spasmodic torticollis to botulinum A toxin injection: a critical evaluation of five cases. Clinical Neurology and Neurosurgery 92:165-168.
16. Pickett AM and Hambleton P (1994). Potency equivalence of botulinum toxin preparations. Journal of the Royal Society of Medicine 87:719.
17. Sanders DB, Massey EW and Buckley EG (1986). Botulinum toxin for blepharospasm: Single-fiber EMG studies. Neurology 36:545-547.
18. Squire JM (1975). Muscle filament structure and muscle contraction. Annual Review of Biophysics and Bioengineering 4:137-163.